Key Points
- Insider sale: Karl Dahlquist sold 9,370 AtriCure shares for approximately $458,099 at an average price of $48.89, reducing his direct stake by 9.69% to 87,319 shares.
- Financial performance: AtriCure reported quarterly EPS of $0.18, beating expectations of $0.13, while revenue of $153.6 million exceeded estimates of $151.8 million. The company issued fiscal 2026 EPS guidance of $0.24–$0.32.
- Market outlook: Analysts maintain a “Moderate Buy” consensus with a $48.62 average price target, while institutional investors own 99.11% of the stock. Shares opened at $48.17, near their 52-week high of $49.88.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Karl Dahlquist sold 9,370 shares of the firm's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the sale, the insider directly owned 87,319 shares in the company, valued at approximately $4,269,025.91. This represents a 9.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
AtriCure Trading Down 1.0%
NASDAQ:ATRC opened at $48.17 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The business's 50-day simple moving average is $37.09 and its 200-day simple moving average is $32.06. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $49.88. The stock has a market capitalization of $2.45 billion, a PE ratio of 229.39 and a beta of 1.20.
AtriCure (NASDAQ:ATRC - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million during the quarter, compared to analysts' expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On AtriCure
Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company's stock valued at $193,993,000 after purchasing an additional 62,861 shares during the last quarter. BlackRock Inc. acquired a new position in AtriCure during the second quarter worth $125,198,000. Wellington Management Group LLP grew its position in AtriCure by 8.1% in the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company's stock valued at $151,296,000 after purchasing an additional 322,818 shares in the last quarter. California State Teachers Retirement System grew its position in AtriCure by 2,627.3% in the second quarter. California State Teachers Retirement System now owns 1,634,927 shares of the medical device company's stock valued at $45,745,000 after purchasing an additional 1,574,980 shares in the last quarter. Finally, First Light Asset Management LLC increased its stake in AtriCure by 32.0% in the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company's stock valued at $46,501,000 after buying an additional 285,083 shares during the last quarter. 99.11% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts recently commented on ATRC shares. UBS Group dropped their price objective on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Wall Street Zen lowered shares of AtriCure from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 2nd. BTIG Research upped their target price on shares of AtriCure from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Monday. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the stock a "buy" rating in a report on Wednesday, May 6th. Finally, Citigroup restated a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $48.62.
Check Out Our Latest Analysis on AtriCure
AtriCure Company Profile
(
Get Free Report)
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
